Halozyme Therapeutics (HALO) EBITDA Margin (2009 - 2026)
Halozyme Therapeutics (HALO) reported EBITDA Margin of 66.87% for Q2 2026, down 1.56 percentage points from 68.43% a year earlier but up 8.94 percentage points from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) EBITDA Margin (2009 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Halozyme Therapeutics' EBITDA Margin came in at 42.80%, down 22.05 percentage points year-over-year; for FY2025, it came in at 39.89%, down 22.44 percentage points from FY2024.
- EBITDA Margin has a five-year change of -15.25 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at 62.33% in FY2024 (+11.38 pp), 50.94% in FY2023 (+2.89 pp), 48.05% in FY2022 (-14.86 pp) and 62.91% in FY2021 (+7.77 pp).
- Five-year quarterly EBITDA Margin spans a low of -14.66% in Q4 2025 and a high of 68.43% in Q2 2025.
- Year over year, EBITDA Margin has now declined in each of the last three quarters, with an average year-over-year change of -5.69 percentage points over the last eight quarters.
- The high point for year-over-year EBITDA Margin in five years was Q2 2023 (a gain of 21.51 percentage points); the low point was Q4 2025 (a drop of 80.41 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at 57.94% (Q1 2026), -14.66% (Q4 2025) and 67.29% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Halozyme Therapeutics | 11.73 Bn | 9.97 Bn | 410.50 Mn | 67.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 67.22% |
| Jun 30, 2026 | 67.34% |
| Mar 31, 2026 | 58.53% |
| Dec 31, 2025 | -14.23% |
| Sep 30, 2025 | 67.81% |
| Jun 30, 2025 | 69.00% |
| Mar 31, 2025 | 61.86% |
| Dec 31, 2024 | 66.37% |
| Sep 30, 2024 | 63.91% |
| Jun 30, 2024 | 60.27% |
| Mar 31, 2024 | 60.03% |
| Dec 31, 2023 | 53.70% |
| Sep 30, 2023 | 52.37% |
| Jun 30, 2023 | 52.89% |
| Mar 31, 2023 | 46.93% |
| Dec 31, 2022 | 45.99% |
| Sep 30, 2022 | 55.70% |
| Jun 30, 2022 | 31.29% |
| Mar 31, 2022 | 66.03% |
| Dec 31, 2021 | 57.13% |
API Access
Halozyme Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();